share_log

Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Truist Securities Reiterates Buy on Coherus BioSciences, Maintains $12 Price Target

Truist Securities重申买入Coherus BioSciences,维持12美元的目标价
Benzinga ·  2023/11/28 12:57

Truist Securities analyst Robyn Karnauskas reiterates Coherus BioSciences (NASDAQ:CHRS) with a Buy and maintains $12 price target.

Truist Securities分析师罗宾·卡尔瑙斯卡斯重申了Coherus BioSciences(纳斯达克股票代码:CHRS)的买入并维持12美元的目标股价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发